ASPEN PHARMACARE HOLDINGS LIMITED - Completion of two Transactions with Sandoz

Completion of two Transactions with Sandoz

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) ("Aspen Holdings")
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively "Aspen" or "the Group")

COMPLETION OF TRANSACTIONS WITH SANDOZ INVOLVING (1) THE ACQUISITION OF SANDOZ'S CHINESE
SUBSIDIARY AND (2) THE DISPOSAL TO SANDOZ OF FOUR ANAESTHETIC PRODUCTS IN EUROPE

Shareholders are referred to the announcement of 4 December 2023 wherein it was confirmed that Aspen had
concluded an agreement with Sandoz AG ("Sandoz"), in terms of which Aspen will:

    -   acquire from Sandoz the entire share capital of its subsidiary, Sandoz (China) Pharmaceutical Co.,
        Ltd. ("Sandoz China" and "the Company"), together with the commercialisation rights and related
        intellectual property for:

            -   a portfolio of established products currently commercialised by the Company; and
            -   a pipeline of products to be launched by the Company in the short to medium term

    -   dispose to Sandoz of the commercialisation rights and related intellectual property for four
        anaesthetic products currently sold by Aspen in the European Economic Area.

Aspen is pleased to confirm that the required merger authority approval for the above transactions has been
granted by the Chinese Authority (State Administration for Market Regulation) and that both of the
transactions are anticipated to become effective by the end of the current financial year.

Durban
04 April 2024

Sponsor
Investec Bank Limited

Date: 04-04-2024 11:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.